84 reports of this reaction
2.2% of all AMPHETAMINE SULFATE reports
#7 most reported adverse reaction
RESPIRATORY ARREST is the #7 most commonly reported adverse reaction for AMPHETAMINE SULFATE, manufactured by Azurity Pharmaceuticals, Inc.. There are 84 FDA adverse event reports linking AMPHETAMINE SULFATE to RESPIRATORY ARREST. This represents approximately 2.2% of all 3,842 adverse event reports for this drug.
Patients taking AMPHETAMINE SULFATE who experience respiratory arrest should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RESPIRATORY ARREST is a less commonly reported adverse event for AMPHETAMINE SULFATE, but still significant enough to appear in the safety profile.
In addition to respiratory arrest, the following adverse reactions have been reported for AMPHETAMINE SULFATE:
The following drugs have also been linked to respiratory arrest in FDA adverse event reports:
RESPIRATORY ARREST has been reported as an adverse event in 84 FDA reports for AMPHETAMINE SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
RESPIRATORY ARREST accounts for approximately 2.2% of all adverse event reports for AMPHETAMINE SULFATE, making it a notable side effect.
If you experience respiratory arrest while taking AMPHETAMINE SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.